curativebiotech.comCrawled Nov 21, 2026
Age-related macular degeneration (AMD) damages the macula, affecting central vision and clarity, and typically occurs as people age.
Connectyx entered an exclusive patent license agreement with the National Eye Institute to develop treatments for rare diseases.
Connectyx signed an exclusive evaluation and commercialization option license agreement with the National Cancer Institute for rare disease treatments.
Connectyx announced it would rebrand as Curative Biotechnology and focus on therapies for glioblastoma and late-stage rabies.
Connectyx acquired worldwide rights to develop IMT504, a novel immunotherapy, from Mid-Atlantic BioTherapeutics.
Curative Biotechnology’s Board of Directors adopted a Code of Ethics and Business Conduct to promote ethical behavior and compliance.
Curative Biotechnology reports progress in its topical metformin-based ophthalmic therapies for degenerative eye diseases. The company highlights achievements in ophthalmology, intellectual property, and translational development over the past year. These milestones advance its pipeline of treatments targeting vision loss conditions.
Curative Biotechnology secures a U.S. patent allowance for its topical metformin eye-drop therapy targeting retinal degeneration, including age-related macular degeneration. The company develops ophthalmic treatments for degenerative eye diseases using metformin-based formulations. This patent strengthens its intellectual property position in the ophthalmology drug development space.
Curative Biotechnology partners with PennVet to test GMP-grade metformin eye drops in a canine model, aiming to support both human and veterinary therapeutic development. The study evaluates the formulation’s safety and efficacy in dogs, bridging preclinical research for degenerative eye disease treatments. The collaboration aligns with Curative’s focus on translational ophthalmology programs.
Curative Biotechnology implements a reverse stock split to strengthen its capital structure while advancing clinical development for degenerative eye disease treatments. The company, currently trading on OTC Markets, targets an uplisting to the OTCQB tier to enhance visibility and investor confidence. Progress in its pipeline focuses on novel therapies for conditions affecting retinal health.
Curative Biotechnology secures a Canadian patent allowance for its metformin-based eye drop formulation targeting retinal degeneration. The company develops treatments for degenerative eye diseases, leveraging metformin—a drug repurposed for ocular applications. The patent advance strengthens intellectual property protection for its pipeline of ophthalmic therapies.
Curative Biotechnology outlines a strategic update and new initiatives to create shareholder value. The development-stage biotech company focuses on novel treatments for degenerative eye diseases. The update follows a letter to shareholders detailing revised plans for advancing its pipeline.
Curative Biotechnology Inc. nominates Dr. Theresa Heah to join its Board of Directors. The company specializes in developing treatments for degenerative eye diseases and operates as a development-stage biomedical firm. Dr. Heah’s appointment is expected to take effect immediately, adding expertise to the board.